December 2011
Johnson & Johnson reduces Tylenol dosage requirements
- Thu, 12/29/2011 - 4:25pm
- Comments
Earlier this year, Johnson & Johnson announced that they have decided to reduce the maximum daily dosage amounts of Extra Strength Tylenol pain reliever in an attempt to lower overdose risks of
Three bellwether trials against Merck scheduled for 2012
- Tue, 12/27/2011 - 3:51pm
- Comments
Three bellwether trials are scheduled to take place in 2012 against Merck & Company, manufacturer of the popular bisphosphonate medication known as Fosamax. U.S.
More lawsuits against Merck & Company
- Tue, 12/27/2011 - 3:49pm
- Comments
On December 15, 2011, a Fosamax lawsuit was filed against drug makers Merck & Co.
Actos class action lawsuit filed in Canada
- Tue, 12/27/2011 - 3:48pm
- Comments
A class action lawsuit has been filed on behalf of consumers who have developed bladder cancer after taking the popular diabetes medication, Actos, manufactured by Japan’s largest drug maker Takeda
Tylenol liver damage lawsuit filed in Puerto Rico
- Tue, 12/27/2011 - 3:13pm
- Comments
A Puerto Rican native and her family have recently filed a Tylenol liver damage lawsuit against Johnson & Johnson, the maker of Extra
The Cooper Companies under investigation
- Tue, 12/27/2011 - 2:53pm
- Comments
Certain directors and officers at The Cooper Companies, parent company to CooperVision®, are being investigated by a law firm on behalf of shareholders.
Fosamax linked to more problems
- Thu, 12/22/2011 - 3:35pm
- Comments
Fosamax, a bisphosphonate drug, was first approved by the Food and Drug Administration (FDA) in 1995 to treat osteoporosis in women.
Wave of lawsuits continue against Takeda Pharmaceuticals
- Thu, 12/22/2011 - 3:34pm
- Comments
Hundreds of thousands of patients who claim there is a linkage between Actos® and bladder cancer are currently filing lawsuits
Settlement Master appointed over Fosamax litigation
- Thu, 12/22/2011 - 3:11pm
- Comments
On November 22, U.S. District Judge John F. Keenan appointed well-respected law professor John D.